Synopsis
Synopsis
0
JDMF
0
EU WC
0
VMF
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 847.0 g/mol |
|---|---|
| Molecular Formula | C46H62N4O11 |
| XLogP3 | 6.3 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 5 |
| Exact Mass | 846.44150881 g/mol |
| Monoisotopic Mass | 846.44150881 g/mol |
| Topological Polar Surface Area | 206 A^2 |
| Heavy Atom Count | 61 |
| Formal Charge | 0 |
| Complexity | 1870 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 9 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 3 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Mycobutin |
| PubMed Health | Rifabutin (By mouth) |
| Drug Classes | Antitubercular |
| Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
| Active Ingredient | Rifabutin |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
| 2 of 4 | |
|---|---|
| Drug Name | Rifabutin |
| PubMed Health | Rifabutin (By mouth) |
| Drug Classes | Antitubercular |
| Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
| Active Ingredient | Rifabutin |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg |
| Market Status | Prescription |
| Company | Lupin |
| 3 of 4 | |
|---|---|
| Drug Name | Rifabutin |
| PubMed Health | Rifabutin (By mouth) |
| Drug Classes | Antitubercular |
| Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
| Active Ingredient | Rifabutin |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg |
| Market Status | Prescription |
| Company | Lupin |
| 4 of 4 | |
|---|---|
| Drug Name | Mycobutin |
| PubMed Health | Rifabutin (By mouth) |
| Drug Classes | Antitubercular |
| Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
| Active Ingredient | Rifabutin |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
90
PharmaCompass offers a list of Rifabutin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Rifabutin manufacturer or Rifabutin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rifabutin manufacturer or Rifabutin supplier.
A AC-19109 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of AC-19109, including repackagers and relabelers. The FDA regulates AC-19109 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. AC-19109 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of AC-19109 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A AC-19109 supplier is an individual or a company that provides AC-19109 active pharmaceutical ingredient (API) or AC-19109 finished formulations upon request. The AC-19109 suppliers may include AC-19109 API manufacturers, exporters, distributors and traders.
click here to find a list of AC-19109 suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A AC-19109 DMF (Drug Master File) is a document detailing the whole manufacturing process of AC-19109 active pharmaceutical ingredient (API) in detail. Different forms of AC-19109 DMFs exist exist since differing nations have different regulations, such as AC-19109 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A AC-19109 DMF submitted to regulatory agencies in the US is known as a USDMF. AC-19109 USDMF includes data on AC-19109's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The AC-19109 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of AC-19109 suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a AC-19109 Drug Master File in Korea (AC-19109 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of AC-19109. The MFDS reviews the AC-19109 KDMF as part of the drug registration process and uses the information provided in the AC-19109 KDMF to evaluate the safety and efficacy of the drug.
After submitting a AC-19109 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their AC-19109 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of AC-19109 suppliers with KDMF on PharmaCompass.
A AC-19109 CEP of the European Pharmacopoeia monograph is often referred to as a AC-19109 Certificate of Suitability (COS). The purpose of a AC-19109 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of AC-19109 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of AC-19109 to their clients by showing that a AC-19109 CEP has been issued for it. The manufacturer submits a AC-19109 CEP (COS) as part of the market authorization procedure, and it takes on the role of a AC-19109 CEP holder for the record. Additionally, the data presented in the AC-19109 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the AC-19109 DMF.
A AC-19109 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. AC-19109 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of AC-19109 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing AC-19109 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for AC-19109 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture AC-19109 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain AC-19109 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a AC-19109 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of AC-19109 suppliers with NDC on PharmaCompass.
AC-19109 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of AC-19109 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right AC-19109 GMP manufacturer or AC-19109 GMP API supplier for your needs.
A AC-19109 CoA (Certificate of Analysis) is a formal document that attests to AC-19109's compliance with AC-19109 specifications and serves as a tool for batch-level quality control.
AC-19109 CoA mostly includes findings from lab analyses of a specific batch. For each AC-19109 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
AC-19109 may be tested according to a variety of international standards, such as European Pharmacopoeia (AC-19109 EP), AC-19109 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (AC-19109 USP).